Prezista Now Available In The UK

Tibotec has announced a new treatment option for children living with HIV. Two new lower dose 75mg and 150mg formulations of Prezista (darunavir) twice daily, co-administered with low-dose ritonavir, are now available for paediatric HIV-1 infected patients. Additionally, the current 600mg darunavir tablet has also been approved for paediatric use.

Dr. Gareth Tudor-Williams, consulting paediatrician at St. Mary’s Hospital, London, said: “With fewer treatment options than adults, the darunavir formulations designed especially for children provide an important new option for these patients. There are approximately two million children living with HIV worldwide, and this is a welcome addition to the treatments we can use to enable them to survive into productive adulthood.”

Paddy McMaster, chair of the Children’s HIV Association, said: “There are a significant number of children living in the UK who have HIV and AIDS. The approval of darunavir for use in children will help us provide excellent care for these kids infected with HIV.”